Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has comple⦠read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
$4.11
Price+0.12%
$0.01
$279.369m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$412k
-
1y CAGR-
3y CAGR-
5y CAGR-$122.474m
-
1y CAGR-
3y CAGR-
5y CAGR-$2.11
-
1y CAGR-
3y CAGR-
5y CAGR-$228.685m
$200.569m
Assets$429.254m
Liabilities$184.333m
Debt91.9%
-1.5x
Debt to EBITDA-$118.898m
-
1y CAGR-
3y CAGR-
5y CAGR